{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:10Z","timestamp":1793321770112,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40618-014-0126-1","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T07:59:58Z","timestamp":1404979198000},"page":"957-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fracture risk assessment before and after resolution of endogenous hypercortisolism: Is the FRAX\u00ae algorithm useful?"],"prefix":"10.1007","volume":"37","author":[{"given":"Laura","family":"Trementino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Ceccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Concettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Michetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Boscaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"126_CR1","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","volume":"88","author":"G Arnaldi","year":"2003","unstructured":"Arnaldi G, Angeli A, Atkinson AB et al (2003) Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593\u20135602","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/BF03345431","volume":"35","author":"G Arnaldi","year":"2012","unstructured":"Arnaldi G, Mancini T, Tirabassi G et al (2012) Advances in the epidemiology, pathogenesis, and management of Cushing\u2019s syndrome complications. J Endocrinol Invest 35:434\u2013448","journal-title":"J Endocrinol Invest"},{"key":"126_CR3","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2009-0612","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Arnaldi G (2009) Approach to the patient with possible Cushing\u2019s syndrome. J Clin Endocrinol Metab 94:3121\u20133131","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","volume":"165","author":"E Valassi","year":"2011","unstructured":"Valassi E, Santos A, Yaneva M et al (2011) The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165:383\u2013392","journal-title":"Eur J Endocrinol"},{"key":"126_CR5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bone.2003.11.026","volume":"34","author":"E Canalis","year":"2004","unstructured":"Canalis E, Bilezikian JP, Angeli A et al (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593\u2013598","journal-title":"Bone"},{"key":"126_CR6","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Staa Van","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224\u20133229","journal-title":"Arthritis Rheum"},{"issue":"3","key":"126_CR7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00198-013-2520-5","volume":"25","author":"L Trementino","year":"2014","unstructured":"Trementino L, Appolloni G, Ceccoli L et al (2014) Bone complications in patients with Cushing\u2019s syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int 25(3):913\u2013921","journal-title":"Osteoporos Int"},{"key":"126_CR8","first-page":"2859","volume":"80","author":"AR Hermus","year":"1995","unstructured":"Hermus AR, Smals AG, Swinkels LM et al (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing\u2019s syndrome. J Clin Endocrinol Metab 80:2859\u20132865","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2265.2003.01713.x","volume":"58","author":"C Somma Di","year":"2003","unstructured":"Di Somma C, Pivonello R, Loche S et al (2003) Effect of 2\u00a0years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing\u2019s disease: a prospective study. Clinical Endocrinol Oxf 58:302\u2013308","journal-title":"Clinical Endocrinol Oxf"},{"key":"126_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/eje.1.02067","volume":"154","author":"C Kristo","year":"2006","unstructured":"Kristo C, Jemtland R, Ueland T et al (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing\u2019s syndrome: a prospective, long-term study. Eur J Endocrinol 154:109\u2013118","journal-title":"Eur J Endocrinol"},{"key":"126_CR11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s00268-007-9394-7","volume":"32","author":"A Kawamata","year":"2008","unstructured":"Kawamata A, Iihara M, Okamoto T et al (2008) Bone mineral density before and after surgical cure of Cushing\u2019s syndrome due to adrenocortical adenoma: prospective study. World J Surg 32:890\u2013896","journal-title":"World J Surg"},{"key":"126_CR12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11102-011-0306-3","volume":"15","author":"ME Randazzo","year":"2012","unstructured":"Randazzo ME, Grossrubatscher E, Dalino Ciaramella P et al (2012) Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 15:193\u2013201","journal-title":"Pituitary"},{"key":"126_CR13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1460051","volume":"146","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, Lindholm J, J\u00f8rgensen JO et al (2002) Increased risk of osteoporotic fractures in patients with Cushing\u2019s syndrome. Eur J Endocrinol 146:51\u201356","journal-title":"Eur J Endocrinol"},{"key":"126_CR14","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257\u20132276","journal-title":"Osteoporos Int"},{"key":"126_CR15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2265.1998.00486.x","volume":"48","author":"C Somma Di","year":"1998","unstructured":"Di Somma C, Colao A, Pivonello R et al (1998) Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing\u2019s disease. Clin Endocrinol Oxf 48:655\u2013662","journal-title":"Clin Endocrinol Oxf"},{"issue":"1","key":"126_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12189","volume":"79","author":"M T\u00f3th","year":"2013","unstructured":"T\u00f3th M, Grossman A (2013) Glucocorticoid-induced osteoporosis: lessons from Cushing\u2019s syndrome. Clin Endocrinol Oxf 79(1):1\u201311","journal-title":"Clin Endocrinol Oxf"},{"issue":"2","key":"126_CR17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00198-013-2588-y","volume":"25","author":"A Scillitani","year":"2013","unstructured":"Scillitani A, Mazziotti G, Di Somma C et al (2013) Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 25(2):441\u2013446","journal-title":"Osteoporos Int"},{"key":"126_CR18","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BM, Findling JW et al (2008) The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526\u20131540","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"126_CR19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","volume":"16","author":"JT Schousboe","year":"2013","unstructured":"Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 16(8):455\u2013566","journal-title":"J Clin Densitom"},{"key":"126_CR20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, Van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"126_CR21","unstructured":"Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK 2007. http:\/\/www.shef.ac.uk\/FRAX\/pdfs\/WHO_Technical_Report.pdf"},{"key":"126_CR22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u2013397","journal-title":"Osteoporos Int"},{"key":"126_CR23","unstructured":"World Health Organization 2007 WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Summary Meeting Report, Brussels, Belgium. www.who.int\/chp\/topics\/rheumatic\/en\/index.html . Accessed 5\u20137 May 2004"},{"key":"126_CR24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","volume":"18","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033\u20131046","journal-title":"Osteoporos Int"},{"key":"126_CR25","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res Hoboken 62:1515\u20131526","journal-title":"Arthritis Care Res Hoboken"},{"key":"126_CR26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2265.2011.03994.x","volume":"74","author":"J Compston","year":"2011","unstructured":"Compston J (2011) Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis? Clin Endocrinol Oxf 74:547\u2013550","journal-title":"Clin Endocrinol Oxf"},{"key":"126_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF03345601","volume":"31","author":"I Chiodini","year":"2008","unstructured":"Chiodini I, Torlontano M, Carnevale V et al (2008) Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest 31:267\u2013276","journal-title":"J Endocrinol Invest"},{"key":"126_CR28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2265.2002.01602.x","volume":"57","author":"CM Francucci","year":"2002","unstructured":"Francucci CM, Pantanetti P, Garrapa GG et al (2002) Bone metabolism and mass in women with Cushing\u2019s syndrome and adrenal incidentaloma. Clin Endocrinol Oxf 57:587\u2013593","journal-title":"Clin Endocrinol Oxf"},{"key":"126_CR29","unstructured":"National Osteoporosis Foundation. Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis 2013. http:\/\/www.nof.org\/files\/nof\/public\/content\/resource\/913\/files\/580.pdf"},{"key":"126_CR30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399\u2013428","journal-title":"Osteoporos Int"},{"key":"126_CR31","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J 182:1864\u20131873","journal-title":"Can Med Assoc J"},{"key":"126_CR32","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman AB et al (2006) Cushing\u2019s syndrome. Lancet 367:1605\u20131617","journal-title":"Lancet"},{"key":"126_CR33","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller BM, Grossman AB, Stewart PM et al (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"126_CR34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A et al (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809\u2013816","journal-title":"Osteoporos Int"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-014-0126-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0126-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:09:23Z","timestamp":1559502563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-014-0126-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["126"],"URL":"https:\/\/doi.org\/10.1007\/s40618-014-0126-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,11]]}}}